ALK and non-small cell lung carcinoma: This step-up dosing regimen reduced the frequency of adverse events while maximizing the potential for efficacy and has demonstrated a favorable benefit–risk profile in both the first-line setting and in patients with ALK+ NSCLC refractory to prior ALK TKI therapy [7–9].